A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells
MetadataShow full item record
MBD4 binds to methylated DNA and acts as a thymine DNA glycosylase in base excision repair. Deficiency of MBD4 in mice enhances mutation at CpG sites and alters apoptosis in response to DNA damage, but does not increase tumorigenesis in mismatch repair-deficient mice. However, in humans, frameshift mutation of MBD4, rather than deletion, is what occurs in up to 43% of microsatellite unstable colon cancers. There is no murine equivalent of this mutation. We now show that recombinant truncated MBD4 (MBD4(tru)) inhibits glycosylase activities of normal MBD4 or Uracil DNA glycosylase in cell-free assays as a dominant negative effect. Furthermore, overexpression of MBD4(tru) in Big Blue (lacI)-transfected, MSI human colorectal carcinoma cells doubled mutation frequency, indicating that the modest dominant negative effect on DNA repair can occur in living cells in short-term experiments. Intriguingly, the whole mutation spectrum was increased, not only at CpG sites, suggesting that truncated MBD4 has a more widespread effect on genomic stability. This demonstration of a dominant negative effect may be of significance in tumour progression and acquisition of drug resistance.
Bader , S A , Walker , M & Harrison , D J 2007 , ' A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells ' , British Journal of Cancer , vol. 96 , no. 4 , pp. 660-666 . https://doi.org/10.1038/sj.bjc.6603592
British Journal of Cancer
Copyright 2007 Cancer Research UK All rights reserved. 12 months after publication this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.